Agenus/LinkedIn
May 13, 2025, 07:27
Agenus Shared Q1 2025 Financial Results and Immuno-Oncology Pipeline Updates
Agenus shared a post on LinkedIn:
“Today we shared our Q1 2025 financial results and highlighted key updates from our immuno-oncology pipeline, including the latest data on botensilimab and balstilimab in the neoadjuvant setting across solid tumors.
We remain committed to advancing the next generation of immunotherapies for individuals living with cancer.
Access the Q1 report.”
More posts featuring Immuno-Oncology on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 19, 2025, 11:05
Jul 19, 2025, 10:29
Jul 19, 2025, 10:12
Jul 19, 2025, 09:55
Jul 19, 2025, 09:05
Jul 19, 2025, 08:54
Jul 19, 2025, 07:24
Jul 19, 2025, 07:23